Fate Therapeutics (F6T) Stock Statistics & Valuation Metrics
Total Valuation
Fate Therapeutics has a market cap or net worth of EUR 223.16M. The enterprise value is EUR 246.98M.
- Market Cap
- EUR 223.16M
- Enterprise Value
- EUR 246.98M
Share Statistics
Fate Therapeutics has 119,820,510 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 119,820,510
- Owned by Insiders
- 12.42%
- Owned by Institutions
- 22.03%
Financial Efficiency
Fate Therapeutics’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -51.39%.
- Return on Equity (ROE)
- -0.66
- Return on Assets (ROA)
- -0.43
- Return on Invested Capital (ROIC)
- -51.39%
- Return on Capital Employed (ROCE)
- -0.52
- Revenue Per Employee
- 41.28K
- Profits Per Employee
- -846.68K
- Employee Count
- 161
- Asset Turnover
- 0.02
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Fate Therapeutics is -1.98. Fate Therapeutics’s PEG ratio is -0.06.
- PE Ratio
- -1.98
- PS Ratio
- 37.35
- PB Ratio
- 1.63
- Price to FCF
- -2.29
- Price to Operating Cash Flow
- -2.46
- PEG Ratio
- -0.06
Income Statement
In the last 12 months, Fate Therapeutics had revenue of 6.65M and earned -136.31M in profits. Earnings per share was -1.15.
- Revenue
- 6.65M
- Gross Profit
- -6.25M
- Operating Income
- -147.70M
- Pretax Income
- -136.31M
- Net Income
- -136.31M
- EBITDA
- -127.02M
- Earnings Per Share (EPS)
- -1.15
Cash Flow
In the last 12 months, operating cash flow was -101.94M and capital expenditures -3.71M, giving a free cash flow of -105.66M billion.
- Operating Cash Flow
- -101.94M
- Free Cash Flow
- -105.66M
- Free Cash Flow per Share
- -0.88
Dividends & Yields
Fate Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -43.58%
- Earnings Yield
- -50.31%
Stock Price Statistics
- Beta
- 1.58
- 52-Week Price Change
- 64.60%
- 50-Day Moving Average
- 1.96
- 200-Day Moving Average
- 1.66
- Relative Strength Index (RSI)
- 48.20
- Average Volume (3m)
- 665
Important Dates
Fate Therapeutics upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Mar 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Fate Therapeutics as a current ratio of 5.79, with Debt / Equity ratio of 37.57%
- Current Ratio
- 5.79
- Quick Ratio
- 5.79
- Debt to Market Cap
- 0.63
- Net Debt to EBITDA
- -0.25
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Fate Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Fate Therapeutics EV to EBITDA ratio is -2.50, with an EV/FCF ratio of -2.70.
- EV to Sales
- 44.01
- EV to EBITDA
- -2.50
- EV to Free Cash Flow
- -2.70
- EV to Operating Cash Flow
- -2.80
Balance Sheet
Fate Therapeutics has EUR 153.77M in cash and marketable securities with EUR 75.67M in debt, giving a net cash position of EUR 78.09M billion.
- Cash & Marketable Securities
- EUR 153.77M
- Total Debt
- EUR 75.67M
- Net Cash
- EUR 78.09M
- Net Cash Per Share
- EUR 0.65
- Tangible Book Value Per Share
- EUR 1.27
Margins
Gross margin is -343.01%, with operating margin of -2058.08%, and net profit margin of -1941.09%.
- Gross Margin
- -343.01%
- Operating Margin
- -2058.08%
- Pretax Margin
- -1941.09%
- Net Profit Margin
- -1941.09%
- EBITDA Margin
- -1762.49%
- EBIT Margin
- -1947.17%
Analyst Forecast
The average price target for Fate Therapeutics is EUR 5.93, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 5.93
- Price Target Upside
- 223.80% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- -28.37%
- EPS Growth Forecast
- 32.58%
Scores
- Smart Score
- 5
- AI Score
- ―
